GSK’s Breo Ellipta Approved With COPD Airflow Obstruction, Exacerbation Claims
This article was originally published in The Pink Sheet Daily
Once-daily dosing provides a convenience advantage over the other inhaled corticosteroid/long-acting beta-agonist combination products on the COPD market: GlaxoSmithKline’s own Advair and AstraZeneca’s Symbicort.
You may also be interested in...
Should using adult data to label a product for kids be ‘a judgment call?’ Advisory committee asks whether FDA needs more explicit criteria during review of GSK’s Breo Ellipta.
FDA advisory committee votes recommends Breo Ellipta for asthma in adults with post-approval safety study, but panel wants additional premarket efficacy and safety data for adolescents.
FDA’s Pulmonary-Allergy Drugs and Drug Safety and Risk Management advisors will cast separate votes March 19 on GSK’s ICS/LABA combo for patients 12-17 and for adults 18 and older.